TABLE 1

Patient Demographics and ¹⁸F-FDG PET Response of the 23 Patients in the Study, with Patients Grouped According to CT Response Attained After 1 Cycle of Chemotherapy

	CT response
Patient demographics	PR	SD	nm
No. of patients (%)	7 (30)	13 (57)	3 (13)
Age (y)
Median	67	64	67
Range	61–71	54–75	52–73
Male sex (%)	5 (71)	12 (92)	3 (100)
Baseline TGV (SUV·mL)
Median	3,372	5,056	844^*
Range	278–16,101	897–15,810	834–853
Baseline SUVmax (SUV)
Median	12.2	12.8	6.4^*
Range	5.4–13.9	5.5–18.1	5.3–7.5
TGV1/TGV0 (%)^†
Median	30	71	92^*
Range	11–71	8–113	83–101
SUVmax1/SUVmax0 (%)^‡
Median	59	80	98^*
Range	39–72	40–111	92–103

↵* A TGV or SUVmax measurement could be obtained in only 2 of 3 patients. Therefore, median and range are derived from only 2 data points.
↵† TGV after 1 cycle of chemotherapy divided by baseline TGV value and expressed as a percentage.
↵‡ SUVmax after 1 cycle of chemotherapy divided by baseline SUVmax value and expressed as a percentage.
PR = partial response; SD = stable disease; nm = not measurable.